To improve care and to facilitate genotype–phenotype predictions for NS‐PME patients, we systematically reviewed all reported GOSR2 mutations, clinical phenotypes, and pathophysiological findings. This evidence concerns the gene GOSR2 and progressive myoclonus epilepsy.